91�㽶��Ƶ

91�㽶��Ƶ today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2021 in the United States.

91�㽶��Ƶ has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics, Inc. (Nasdaq: ACOR), a developer of therapies to restore function and improve the lives of people with neurological disorders.

Novan today announced an agreement with 91�㽶��Ƶ for the development of an intranasal formulation of berdazimer sodium for use in Novan’s COVID-19 program.

91�㽶��Ƶ today announced the appointment of Nakaya “Nick” Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Passage Bio, Inc. and 91�㽶��Ƶ today announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic CNS disorders.

91�㽶��Ƶ today announced that it is investing $10 million in isolator capabilities at its sites in Malvern, Pennsylvania and Dartford, U.K., to expand its micronization capabilities for highly potent drug compounds.

91�㽶��Ƶ today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib).

91�㽶��Ƶ appoints Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. Dr. Mahdavi will join a team of experts to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques.

91�㽶��Ƶ has completed the acquisition of Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium.